Suloctidil | CAS# 54767-75-8 | vasodilator

MedKoo Cat#: 329474 | Name: Suloctidil

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Suloctidil was a sulfer-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator. In 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity. Suloctidil more potently inhibited calcium-induced contractions in small arteries (mesenteric and saphenous artery), than in the aorta. Suloctidil also reduced the tonic component of the responses to norepinephrine. In contrast to the effects on calcium-induced contractions, the effects of suloctidil on norepinephrine-induced responses was mainly noncompetitive.

Chemical Structure

Suloctidil

CAS# 54767-75-8

Theoretical Analysis

MedKoo Cat#: 329474

Name: Suloctidil

CAS#: 54767-75-8

Chemical Formula: C20H35NOS

Exact Mass: 337.2439

Molecular Weight: 337.57

Elemental Analysis: C, 71.16; H, 10.45; N, 4.15; O, 4.74; S, 9.50

Price and Availability

Size	Price	Availability
200mg	USD 250.00	2 Weeks
500mg	USD 450.00	2 Weeks
1g	USD 650.00	2 Weeks
2g	USD 950.00	2 Weeks
5g	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Suloctidil; Bemperil; Cerebro; Circleton; CP 556 S; CP 556S; CP-556S; Daufan; Dulai; Hemoantin; MJF 12637; Octamet; Polivasal; Ravenil; Sudil.

IUPAC/Chemical Name

(1R,2S)-1-(4-(isopropylthio)phenyl)-2-(octylamino)propan-1-ol

InChi Key

BFCDFTHTSVTWOG-PXNSSMCTSA-N

InChi Code

InChI=1S/C20H35NOS/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3/h11-14,16-17,20-22H,5-10,15H2,1-4H3/t17-,20-/m0/s1

SMILES Code

O[C@@H]([C@@H](NCCCCCCCC)C)C1=CC=C(SC(C)C)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 337.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chauvet-Monges AM, Faure R, Crevat A. 1H-NMR study of suloctidil-A23187 calcium ionophore interaction. Chem Biol Interact. 1993 Feb;86(2):163-9. PubMed PMID: 8383582. 2: Butts A, DiDone L, Koselny K, Baxter BK, Chabrier-Rosello Y, Wellington M, Krysan DJ. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot Cell. 2013 Feb;12(2):278-87. doi: 10.1128/EC.00314-12. PubMed PMID: 23243064; PubMed Central PMCID: PMC3571299. 3: Bucchi F, Cerletti C, de Gaetano G. Inhibition of platelet thromboxane generation by suloctidil in man. Haemostasis. 1986;16(5):362-8. PubMed PMID: 3023210. 4: Turpie AG, Gent M, Doyle DJ, Saerens E, de Boer AC, Talbot C, McNamee J, Hirsh J. An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. Thromb Res. 1985 Jul 15;39(2):173-81. PubMed PMID: 2992116. 5: Ishibashi A, Hanagata R, Horii D, Hisayama T, Takayanagi I. [Effect of suloctidil on the contractions of isolated rat aortic strips induced by norepinephrine and CaCl2]. Nihon Yakurigaku Zasshi. 1983 Nov;82(5):361-73. Japanese. PubMed PMID: 6323288. 6: Takahashi K, Arai Y. [Antigenicity of suloctidil]. J Toxicol Sci. 1983 Aug;8(3):231-42. Japanese. PubMed PMID: 6319726. 7: Nishi H, Kadowaki S, Endo N. [Effect of suloctidil in the protection of the cerebral function]. Nihon Yakurigaku Zasshi. 1983 Jul;82(1):37-46. Japanese. PubMed PMID: 6311699. 8: Calderon P, van Dorsser W, Geöcze von Szendroi K, De Mey JG, Roba J. In vitro vasorelaxing activity of suloctidil. Arch Int Pharmacodyn Ther. 1986 Nov;284(1):101-13. PubMed PMID: 3030204. 9: Gent M, Blakely JA, Hachinski V, Roberts RS, Barnett HJ, Bayer NH, Carruthers SG, Collins SM, Gawel MG, Giroux-Klimek M, et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke. 1985 May-Jun;16(3):416-24. PubMed PMID: 2988158. 10: Horii D, Ishibashi A, Sano F. [Effect of suloctidil on the dynamics of the peripheral artery of the dog]. Nihon Yakurigaku Zasshi. 1983 Jul;82(1):67-78. Japanese. PubMed PMID: 6311700. 11: Chieffo C, Postiglione A, Tritto C, Mancini M. Hypocholesterolaemic activity of suloctidil: double-blind, crossover short-term and long-term treatment trial. Curr Med Res Opin. 1984;9(3):147-52. PubMed PMID: 6094103. 12: Boeynaems JM, Van Coevorden A, Demolle D. Stimulation of prostacyclin production in blood vessels by the antithrombotic drug suloctidil. Biochem Pharmacol. 1987 May 15;36(10):1629-35. PubMed PMID: 3036152. 13: Wolf DL, Hall ED. Suloctidil treatment prevents the development of post-traumatic feline spinal cord ischemia. Arch Int Pharmacodyn Ther. 1985 Mar;274(1):139-44. PubMed PMID: 2990364. 14: Chatelain P, Demol D, Roba J. Inhibition by suloctidil of [3H] nitrendipine binding to cerebral cortex membranes. Biochem Pharmacol. 1984 Apr 1;33(7):1099-103. PubMed PMID: 6324812. 15: Montefusco O, Missale C, Govoni S, Rozzini R, Trabucchi M. Effect of suloctidil on dopaminergic transmission in various rat brain areas: possible uses as drug for the elderly. Pharmacol Res Commun. 1983 Mar;15(3):317-27. PubMed PMID: 6304786. 16: Tkaczewski W, Buczyński A, Dziedziczak-Buczyńska M, Wachowicz B, Kedziora J. [The effect of suloctidil and acetylsalicylic acid on eicosanoid synthesis in human platelets]. Pol Tyg Lek. 1992 Oct 19-26;47(42-43):970-1. Polish. PubMed PMID: 1338656. 17: De Paermentier F, Heuschling P, Knoops B, Janssens De Varebeke P, Pauwels G, Laszlo De Kaszon-Jakabfalva C, Van den Bosch De Aguilar P. Suloctidil increases the rat brain cortex microvascular regeneration after a lesion. Life Sci. 1989;44(1):41-7. PubMed PMID: 2464117. 18: Thines-Sempoux D, Bovy-Kesler C, Debruyne E, Roba J. Effect of suloctidil on rat liver. Arch Toxicol. 1986 Jul;59(2):115-20. PubMed PMID: 3019276. 19: Stratton JR, Ritchie JL. Effect of suloctidil on tomographically quantitated platelet accumulation in Dacron aortic grafts. Am J Cardiol. 1986 Jul 1;58(1):152-6. PubMed PMID: 3014851. 20: Hanson SR, Harker LA. Studies of suloctidil in experimental thrombosis in baboons. Thromb Haemost. 1985 Jun 24;53(3):423-7. PubMed PMID: 2996168.